Historical Valuation
Agios Pharmaceuticals Inc (AGIO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.14 is considered Undervalued compared with the five-year average of -1.64. The fair price of Agios Pharmaceuticals Inc (AGIO) is between 34.25 to 51.51 according to relative valuation methord. Compared to the current price of 28.16 USD , Agios Pharmaceuticals Inc is Undervalued By 17.78%.
Relative Value
Fair Zone
34.25-51.51
Current Price：28.16
17.78%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Agios Pharmaceuticals Inc (AGIO) has a current Price-to-Book (P/B) ratio of 1.23. Compared to its 3-year average P/B ratio of 1.83 , the current P/B ratio is approximately -32.71% higher. Relative to its 5-year average P/B ratio of 1.99, the current P/B ratio is about -38.11% higher. Agios Pharmaceuticals Inc (AGIO) has a Forward Free Cash Flow (FCF) yield of approximately -26.13%. Compared to its 3-year average FCF yield of -19.10%, the current FCF yield is approximately 36.80% lower. Relative to its 5-year average FCF yield of -19.00% , the current FCF yield is about 37.52% lower.
P/B
Median3y
1.83
Median5y
1.99
FCF Yield
Median3y
-19.10
Median5y
-19.00
Competitors Valuation Multiple
AI Analysis for AGIO
The average P/S ratio for AGIO competitors is 8.01, providing a benchmark for relative valuation. Agios Pharmaceuticals Inc Corp (AGIO.O) exhibits a P/S ratio of 20.14, which is 151.56% above the industry average. Given its robust revenue growth of 43.69%, this premium appears sustainable.
Performance Decomposition
AI Analysis for AGIO
1Y
3Y
5Y
Market capitalization of AGIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AGIO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AGIO currently overvalued or undervalued?
Agios Pharmaceuticals Inc (AGIO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.14 is considered Undervalued compared with the five-year average of -1.64. The fair price of Agios Pharmaceuticals Inc (AGIO) is between 34.25 to 51.51 according to relative valuation methord. Compared to the current price of 28.16 USD , Agios Pharmaceuticals Inc is Undervalued By 17.78% .
What is Agios Pharmaceuticals Inc (AGIO) fair value?
AGIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Agios Pharmaceuticals Inc (AGIO) is between 34.25 to 51.51 according to relative valuation methord.
How does AGIO's valuation metrics compare to the industry average?
The average P/S ratio for AGIO's competitors is 8.01, providing a benchmark for relative valuation. Agios Pharmaceuticals Inc Corp (AGIO) exhibits a P/S ratio of 20.14, which is 151.56% above the industry average. Given its robust revenue growth of 43.69%, this premium appears sustainable.
What is the current P/B ratio for Agios Pharmaceuticals Inc (AGIO) as of Jan 10 2026?
As of Jan 10 2026, Agios Pharmaceuticals Inc (AGIO) has a P/B ratio of 1.23. This indicates that the market values AGIO at 1.23 times its book value.
What is the current FCF Yield for Agios Pharmaceuticals Inc (AGIO) as of Jan 10 2026?
As of Jan 10 2026, Agios Pharmaceuticals Inc (AGIO) has a FCF Yield of -26.13%. This means that for every dollar of Agios Pharmaceuticals Inc’s market capitalization, the company generates -26.13 cents in free cash flow.
What is the current Forward P/E ratio for Agios Pharmaceuticals Inc (AGIO) as of Jan 10 2026?
As of Jan 10 2026, Agios Pharmaceuticals Inc (AGIO) has a Forward P/E ratio of -3.73. This means the market is willing to pay $-3.73 for every dollar of Agios Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Agios Pharmaceuticals Inc (AGIO) as of Jan 10 2026?
As of Jan 10 2026, Agios Pharmaceuticals Inc (AGIO) has a Forward P/S ratio of 20.14. This means the market is valuing AGIO at $20.14 for every dollar of expected revenue over the next 12 months.